Passing of Dr Sue Foden, Chair
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your TCF notes
Alderley Park, UK - 4 November 2024: TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on oncology and neuropsychiatry announces with deep sadness the sudden passing of Dr Sue Foden, the Company's Chair.
Sue was appointed as a non-executive director to TheraCryf plc (then Evgen Pharma plc) in 2015, becoming Chair in September 2023. Over the past nine years, she has been a valuable advisor and support to the leadership team and Company overall. Her passing is a great loss to the Biotech sector in the UK and beyond.
The Company will seek an additional non-executive director as soon as practicable. Our thoughts are with Sue's family during this difficult time.
Dr Huw Jones, CEO, said:
"On behalf of the Board and all my colleagues at TheraCryf I wanted to express our collective shock and sadness at the news of Sue's passing. Over the years, she showed deep passion and dedication to supporting TheraCryf and its team. Her fierce intellect, deep scientific insights, support and guidance were very important to me and she will be missed by us all."
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.